China is barring a GlaxoSmithKline executive from leaving the country amid a widening $490 bribery scandal ensaring the drug giant.
China is preventing a GlaxoSmithKline executive from leaving the country as police accuse the British drugmaker of bribing officials and doctors, the drugmaker says.
CNBC's Eunice Yoon reports sales at the pharmaceutical giant jumped 20 percent last year but police say bribes may have spiked the gains.
Andrew Weiss, head of pharma and biotech research at Vontobel, , talks about Novartis' quarterly results and outlook and says the company will remain under pressure for the next few quarters.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
China is using "concerted" probes of foreign baby formula, pharmaceutical and packaging companies to bolster domestic firms, according to observers.
Executives of British drug maker GlaxoSmithKline in China have confessed to charges of bribery and tax law violations, China's security ministry said on Thursday.
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Onyx Pharmaceuticals has rejected a $10 billion takeover bid from Amgen, reports CNBC's Bertha Coombs.
Fast Money trader Jon Najarian takes a look at some unusual activity in shares of Onyx Pharmaceuticals. And a play on the biotechnolgy space, with the FMHR crew.
Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.
The American Medical Association says obesity should be classified as a disease. CNBC's Bertha Coombs reports AMA's Patrice Harris says the hope is for doctors to be more proactive in treating obese patients.
Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
The FTC can challenge deals to keep generic drugs off the market, reports CNBC's Hampton Pearson.
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
Pfizer announced a $2.15 billion settlement from Teva Pharmaceuticals and and Sun Pharmaceutical for patent infringement on its drug Protonix.
Matthew Foy, partner, SR One and Peter Silvester, president of Life Technologies, discuss whether personalised medicine is a true disruptor or just for the rich.